. 2019 Jan 2;2019:8947204. doi: 10.1155/2019/8947204

Table 1.

Baseline characteristics and pooled rates data.

First author	Valve type	Bauer 2014	Costopoulos 2014	Kochman 2014	Sannino 2017	Yoon 2017	Relative risk (95%CI; p value)
# of patients	BAV	38	21	28	88	546	NA
# of patients	TAV	1357	447	84	735	546	NA

Devices	BAV	CV, Sapien	CV, Sapien	CV, Sapien	SXT, S3, CV, ER, Lotus	SXT, S3, CV, ER, Lotus	NA
Devices	TAV	CV, Sapien	CV, Sapien	CV, Sapien	SXT, S3, CV, ER, Lotus	SXT, S3, CV, ER, Lotus	NA

Approaches	BAV	TA, TAo, TF	TF, TA, TAx	TF, TA, TAo, TS	TF, TA, TAo, TS	TF	NA
Approaches	TAV	TA, TAo, TF, TAx	TF, TA, TAo, TAx	TF, TA, TAo, TS	TF, TA, TAo, TS	TF	NA

STS Score, %	BAV	-	7.6 ± 4.2	-	7.4 ± 3.9	4.6 ± 4.6	0.04 (-0.06, 0.15; p=0.393)^∗
STS Score, %	TAV	-	7.8 ± 7.3	-	7.6 ± 3.9	4.3 ± 3.0	0.04 (-0.06, 0.15; p=0.393)^∗

EuroScore, %	BAV	18 ± 10	23.9 ± 12.0	19.2 ± 9.0	-	16.1 ± 12.0	-0.07 (-0.17, 0.04; p=0.222)^∗
EuroScore, %	TAV	20 ± 13	24.4 ± 17.3	18.8 ± 8.7	-	16.9 ± 13.9	-0.07 (-0.17, 0.04; p=0.222)^∗

Mean age in years	BAV	80.7 ± 6.6	76.7 ± 7.1	77.6 ± 5.5	80.2 ± 8.4	77.2 ± 8.2	-0.09 (-0.21, 0.03; p=0.156)^∗
Mean age in years	TAV	81.8 ± 6.2	79.8 ± 7.4	79.1 ± 6.8	81.8 ± 7.9	77.2 ± 8.8	-0.09 (-0.21, 0.03; p=0.156)^∗

Females	BAV	55.3	42.9	53.6	39.8	37.2	0.92 (0.82, 1.03; p=0.144)
Females	TAV	58.0	52.6	57.1	47.1	39.4	0.92 (0.82, 1.03; p=0.144)

Mean aortic gradient	BAV	-	54.4 ± 17.9	55.5 ± 17.6	46.9 ± 16.9	49.7 ± 17.7	0.10 (0.00, 0.20; p=0.048)^∗
Mean aortic gradient	TAV	-	52.5 ± 16.0	52.5 ± 18.9	44.3 ± 13.6	48.5 ± 17.1	0.10 (0.00, 0.20; p=0.048)^∗

Mean LVEF	BAV	50 ± 16	50.1 ± 12.4	48.1 ± 13.1	-	51.6 ± 15.0	-0.04 (-0.14, 0.07; p=0.489)^∗
Mean LVEF	TAV	53 ± 15	52.0 ± 12.6	49.8 ± 14.0	-	51.6 ± 15.2	-0.04 (-0.14, 0.07; p=0.489)^∗

NYHA III/IV	BAV	84.2	71.4	71.4	-	-	0.96 (0.86, 1.07; p=0.438)
NYHA III/IV	TAV	89.0	67.3	78.6	-	-	0.96 (0.86, 1.07; p=0.438)

HTN	BAV	-	66.7	60.7	80.7	70.0	0.98 (0.92, 1.04; p=0.457)
HTN	TAV	-	77.2	65.5	83.3	70.5	0.98 (0.92, 1.04; p=0.457)

DM	BAV	36.8	28.6	39.3	33.0	23.4	1.20 (0.80, 1.79, p=0.372)
DM	TAV	34.0	30.2	34.5	38.5	23.3	1.20 (0.80, 1.79, p=0.372)

COPD	BAV	21.1	33.3	21.4	17.0	-	1.00 (0.74, 1.36; p=0.979)
COPD	TAV	24.0	30.6	20.2	20.3	-	1.00 (0.74, 1.36; p=0.979)

CAD	BAV	68.4	-	50.0	69.3	-	1.04 (0.89, 1.21; p=0.631)
CAD	TAV	60.0	-	64.3	66.3	-	1.04 (0.89, 1.21; p=0.631)

PAD	BAV	10.5	33.3	21.4	39.8	15.2	0.99 (0.73, 1.33; p=0.929)
PAD	TAV	22.0	29.8	34.5	29.8	15.6	0.99 (0.73, 1.33; p=0.929)

Prior PCI	BAV	34.2	28.6	21.4	-	22.2	0.95 (0.79, 1.14; p=0.569)
Prior PCI	TAV	35.0	21.5	35.7	-	23.4	0.95 (0.79, 1.14; p=0.569)

CKD (GFR <60 ml/min)	BAV	22	11	12	45	-	1.03 (0.89, 1.20; p=0.665)
CKD (GFR <60 ml/min)	TAV	828	257	36	330	-	1.03 (0.89, 1.20; p=0.665)

Prior CABG	BAV	13.2	14.3	14.3	-	11.4	0.85 (0.65, 1.13; p=0.258)
Prior CABG	TAV	18.0	19.9	25.0	-	12.3	0.85 (0.65, 1.13; p=0.258)

Previous cerebrovascular accident	BAV	13.2	19.0	28.6	19.3	14.1	1.18 (0.95, 1.48; p=0.137)
Previous cerebrovascular accident	TAV	8.0	16.1	16.7	18.0	12.6	1.18 (0.95, 1.48; p=0.137)

∗ = Standardized Mean Difference (SMD).

P value for test of SDM = 0 or relative risk = 1 as appropriate.

BAV = Bicuspid aortic valve; CABG = Coronary artery bypass graft; CAD = Coronary artery disease; CKD = Chronic kidney disease; COPD = Chronic obstructive pulmonary disease; CV = Core Valve; DM = Diabetes mellitus; ER = CoreValve Evolut R; EuroScore = European System for Cardiac Operative Risk Evaluation; GFR = Glomerular filtration rate; HTN = Hypertension; LVEF = Left ventricular ejection fraction; NYHA = New York Heart Association; PAD = Peripheral artery disease; PCI = Percutaneous coronary intervention; S3 = Sapien S3; STS = Society of Thoracic Surgeons; S = Sapien; SXT = Sapien XT; TA = Transapical; TAo = Transaortic; TAV = Tricuspid aortic valve; TAx = Transaxillary; TF = Transfemoral; TS = Transubclavian.